Activation of matrix metalloproteinases (MMPs) by SPARC has been reported in other systems [49], and we investigate the possibility of such a connection in melanoma using a broad spectrum MMP inhibitor [50] on HTB66 cells treated with MSA. The gene discussed is SPARC; the disease is melanoma.